Fenobam - CAS 57653-26-6
Catalog number:
57653-26-6
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C11H11ClN4O2
Molecular Weight:
266.68
COA:
Inquire
Targets:
mGluR
Description:
Fenobam is a potent, selective, noncompetitive glutamate mGluR5 receptor antagonist. It displays inverse agonist properties. It blocks mGluR5 constitutive activity in vitro with IC50 value of 87 nM. It has been used as a lead compound for the development of a range of newer mGluR5 antagonists. It has also shown promising initial results in the treatment of fragile X syndrome. It also displays anxiolytic activity. It was developed by Johnson & Johnson and in clinic phase 2 trials with no progress.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>99 %
Appearance:
White solid
Synonyms:
1-(3-Chlorophenyl)-3-(4,5-dihydro-1-methyl-4-oxo-1H-imidazol-2-yl)urea;NPL-2009;NPL2009
Solubility:
DMSO: >20 mg/mL
Storage:
2-8ºC
MSDS:
Inquire
Application:
Fenobam has been used as a lead compound for the development of a range of newer mGluR5 antagonists. It has also shown promising initial results in the treatment of fragile X syndrome. It also displays anxiolytic activity.
Quality Standard:
In-house standard
Quantity:
Grams to Kilograms
Density:
1.47±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
DWPQODZAOSWNHB-UHFFFAOYSA-N
InChI:
InChI=1S/C11H11ClN4O2/c1-16-6-9(17)14-10(16)15-11(18)13-8-4-2-3-7(12)5-8/h2-5H,6H2,1H3,(H2,13,14,15,17,18)
Canonical SMILES:
CN1CC(=O)N=C1NC(=O)NC2=CC(=CC=C2)Cl
Current Developer:
Fenobam was developed by Johnson & Johnson and in clinic phase 2 trials with no progress.
1.The mGluR5 antagonist fenobam induces analgesic conditioned place preference in mice with spared nerve injury.
Lax NC1, George DC1, Ignatz C1, Kolber BJ1. PLoS One. 2014 Jul 25;9(7):e103524. doi: 10.1371/journal.pone.0103524. eCollection 2014.
Antagonists of metabotropic glutamate receptors (mGluRs) have the potential to act as analgesic drugs that may help alleviate chronic pain. This study was done to look at the possible rewarding properties of the mGluR5 antagonist, fenobam, in a cognitive assay. Analgesic conditioned place preference (aCPP) was used to examine the effects of fenobam (30 mg/kg) and the prototypical mGluR5 antagonist, MPEP, and these effects were compared to those of a drug with known analgesic properties, morphine (10 mg/kg). In each experiment, one group of mice received spared nerve injury (SNI) surgery to model chronic pain; the other group received a control sham surgery. Both fenobam and MPEP induced preference in the SNI mice, such that SNI mice spent significantly more time in the mGluR5 antagonist-paired chamber compared to a vehicle-paired chamber. No such preference developed for sham mice. Morphine induced preference in male and female mice in both the SNI and sham groups.
2.Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Rascol O1, Fox S2, Gasparini F3, Kenney C4, Di Paolo T5, Gomez-Mancilla B6. Parkinsonism Relat Disord. 2014 Sep;20(9):947-56. doi: 10.1016/j.parkreldis.2014.05.003. Epub 2014 May 14.
BACKGROUND: Modulation of metabotropic glutamate receptors may be a novel therapeutic approach to manage L-Dopa-induced dyskinesias in patients with Parkinson's disease. This article reviews the rationale for use of metabotropic glutamate 5-receptor antagonists in experimental and clinical L-Dopa-induced dyskinesias.
3.Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity.
Anighoro A1, Graziani D2, Bettinelli I2, Cilia A2, De Toma C2, Longhi M2, Mangiarotti F2, Menegon S2, Pirona L2, Poggesi E2, Riva C2, Rastelli G3. Bioorg Med Chem. 2015 Jul 1;23(13):3040-58. doi: 10.1016/j.bmc.2015.05.008. Epub 2015 May 12.
Metabotropic glutamate receptor 5 (mGlu5) is a biological target implicated in major neurological and psychiatric disorders. In the present study, we have investigated structural determinants of the interaction of negative allosteric modulators (NAMs) with the seven-transmembrane (7TM) domain of mGlu5. A homology model of the 7TM receptor domain built on the crystal structure of the mGlu1 template was obtained, and the binding modes of known NAMs, namely MPEP and fenobam, were investigated by docking and molecular dynamics simulations. The results were validated by comparison with mutagenesis data available in the literature for these two ligands, and subsequently corroborated by the recently described mGlu5 crystal structure. Moreover, a new series of NAMs was synthesized and tested, providing compounds with nanomolar affinity. Several structural modifications were sequentially introduced with the aim of identifying structural features important for receptor binding.
4.mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex.
LaCrosse AL, Taylor SB, Nemirovsky NE, Gass JT, Olive MF1. CNS Neurol Disord Drug Targets. 2015;14(4):476-85.
Positive and negative allosteric modulators (PAMs and NAMs, respectively) of type 5 metabotropic glutamate receptors (mGluR5) are currently being investigated as novel treatments for neuropsychiatric diseases including drug addiction, schizophrenia, and Fragile X syndrome. However, only a handful of studies have examined the effects of mGluR5 PAMs or NAMs on the structural plasticity of dendritic spines in otherwise naïve animals, particularly in brain regions mediating executive function. In the present study, we assessed dendritic spine density and morphology in pyramidal cells of the medial prefrontal cortex (mPFC) after repeated administration of either the prototypical mGluR5 PAM 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5- yl)benzamide (CDPPB, 20 mg/kg), the clinically utilized mGluR5 NAM 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4Himidazol- 2-yl)urea (fenobam, 20 mg/kg), or vehicle in male Sprague-Dawley rats. Following once daily treatment for 10 consecutive days, coronal brain sections containing the mPFC underwent diolistic labeling and 3D image analysis of dendritic spines.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products


CAS 96206-92-7 MPEP

MPEP
(CAS: 96206-92-7)

MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM, exhibiting no appreciable activity at mGlu1b/2/3/4a/7b/8a/6 receptors.

CAS 635318-11-5 LY404039

LY404039
(CAS: 635318-11-5)

LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II su...

CAS 757950-09-7 Raseglurant

Raseglurant
(CAS: 757950-09-7)

Raseglurant is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP. It can be used for the treatment of migraine, gastroesophageal refl...

CAS 97240-79-4 Topiramate

Topiramate
(CAS: 97240-79-4)

Topiramate is a kainate GluR5 receptor antagonist,originally used as an anticonvulsant.

CAS 125404-04-8 TCN238

TCN238
(CAS: 125404-04-8)

TCN238 is an orally available, brain penetrant and positive allosteric mGlu4 receptor modulator (EC50= 1 μM) with 30-fold selectivity over mGluR5 using human re...

CAS 1246086-78-1 VU 0364439

VU 0364439
(CAS: 1246086-78-1)

CAS 693288-97-0 CPPHA

CPPHA
(CAS: 693288-97-0)

CPPHA is a selective positive allosteric modulator of mGluR5 receptor. It is thought to act at a novel allosteric site and potentiates mGlu5 responses by a mech...

CAS 872363-17-2 Dipraglurant

Dipraglurant
(CAS: 872363-17-2)

Dipraglurant is a mGlu5 receptor negative allosteric modulator. It is currently in phase II for the treatment of dyskinesia in Parkinson's disease.

CAS 1445605-23-1 Lu AF21934

Lu AF21934
(CAS: 1445605-23-1)

Lu AF21934 is a selective and brain-penetrating positive allosteric modulator (PAM) of mGlu4 receptors (IC50= 500 nM) on the harmaline-induced tremor and other ...

ML337
(CAS: 1443118-44-2)

ML337 is a Selective negative allosteric modulator of mGlu3 with IC50 value of 593 nM. It shows no activity at mGlu1, mGlu2 or mGlu4-8 at concentrations up to 3...

CAS 802906-73-6 RG7090

RG7090
(CAS: 802906-73-6)

RG7090 is a negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5).

CAS 219911-35-0 MPEP Hydrochloride

MPEP Hydrochloride
(CAS: 219911-35-0)

Potent and selective antagonist for metabotropic glutamate receptor subtype 5 (mGluR5); Systemically active in vivo.

CAS 543906-09-8 Mavoglurant

Mavoglurant
(CAS: 543906-09-8)

Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist (IC50=30 nM), as a a selective non-competitive antagonist.

FITM
(CAS: 932737-65-0)

FITM is a potent mGlu1 inhibitor (Ki = 2.5 nM) with great selectivity that does not disrupt mGlu5.

CAS 524924-76-3 Methoxy-PEPy

Methoxy-PEPy
(CAS: 524924-76-3)

Methoxy-PEPy is a potent and highly selective mGlu5 receptor antagonist.

CAS 1186195-60-7 MTEP hydrochloride

MTEP hydrochloride
(CAS: 1186195-60-7)

Glutamate, the major excitatory neurotransmitter in the brain, acts on both ionotropic and metabotropic glutamate receptors. Excessive metabotropic glutamate re...

CAS 56-85-9 L-Glutamine

L-Glutamine
(CAS: 56-85-9)

L-Glutamine is one of the 20 amino acids encoded by the standard genetic code.

CAS 232605-26-4 Bay 36-7620

Bay 36-7620
(CAS: 232605-26-4)

BAY 36-7620 elective mGlu1 receptor non-competitive antagonist (IC50 = 0.16 μM) with inverse agonist activity.

CAS 1127498-03-6 JNJ-40411813

JNJ-40411813
(CAS: 1127498-03-6)

JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.

CAS 433967-28-3 VU 0357121

VU 0357121
(CAS: 433967-28-3)

VU0357121 is a novel positive allosteric modulator (PAM) of mGlu5 with EC50 of 33 nM, is inactive or very weakly antagonizing at other mGlu receptor subtypes.

Chemical Structure

CAS 57653-26-6 Fenobam

Quick Inquiry

Verification code

Featured Items